Abstract
BackgroundComplement-binding assays are proposed to better stratify the risk of antibody-mediated rejection associated-graft failure. Despite promising clinical results, some have suggested that the MFI of anti-HLA antibodies may influence these tests. MethodsWe investigated the impact of Abs MFI reduction, induced by plasmapheresis, on C1q- and C3d-binding assays. Sera provided from 7 sensitized kidney transplant patients were analyzed. ResultsFour hundreds and thirty-three SABs were analyzed. Before plasmapheresis, when compared to C1q− SABs, C1q+ SABs had a higher median MFI [17397 (IQR: 14851–18794) vs. 2745 (IQR: 1125–6476), p<0.01]. SABs that remained C1q+ after plasmapheresis had a higher median MFI. Regarding the C3d assay, results were strictly comparable. MFI value was a powerful predictor of both C1q and C3d positivity [AUC 0.97 (CI95% 0.95–0.99) and 0.96, (CI95% 0.93–0.98), respectively]. ConclusionOur data suggest that both C1q- and C3d-binding assays are intimately linked to the MFI of anti-HLA Abs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
